Zebrafish patient derived xenografts for personalised medicine
Project leader: Rita Fior
Despite advances in targeted cancer treatments, we still lack methods to predict how a specific cancer will respond to treatment. Consequently, patients go through rounds-of-trial-and-error approaches based on treatment guidelines to find the best treatment, often subjected to unnecessary toxicity. The gold standard for in vivo assessment of response to therapy are mouse Patient Derived Xenografts (PDX). However, due to time and costs, these are not suitable for clinical practice. We are developing zebrafish-larvae-xenografts as sensors for cancer behavior and personalized therapy screening.